Evidence map›Paper›PMID 33947438›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

The immune cell landscape of metastatic uveal melanoma correlates with overall survival.

Anna Tosi, Rocco Cappellesso, Angelo Paolo Dei Tos, Valentina Rossi, Camillo Aliberti, Jacopo Pigozzo, Alessio Fabozzi, Marta Sbaraglia, Stella Blandamura, Paola Del Bianco and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Highlighting recent achievements to advance more effective cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2025
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Anna TosiDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Rocco CappellessoPathological Anatomy Unit, Padova University Hospital, Padova, Italy.
Angelo Paolo Dei TosPathological Anatomy Unit, Padova University Hospital, Padova, Italy.
Valentina RossiImmunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128, Padova, Italy.
Camillo AlibertiDepartement of Diagnostic & Interventive Radiology-Pederzoli Hospital, Peschiera, VR, Italy.
Jacopo PigozzoMelanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Alessio FabozziDepartment of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Marta SbaragliaPathological Anatomy Unit, Padova University Hospital, Padova, Italy.
Stella BlandamuraDepartment of Medicine (DIMED), Surgical Pathology Unit, University of Padova, Padova, Italy.
Paola Del BiancoClinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Vanna Chiarion-Sileni *Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Antonio Rosato *Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. antonio.rosato@unipd.it.ORCID http://orcid.org/0000-0002-5263-8386
University of Padua · ITIstituto Oncologico Veneto · IT

Funding

5 per Mille 2019 BIOV19ROSATO5 per Mille 2019 ID. 22759Fondazione AIRC IG 2018 -ID. 21354Ministry of Health-Alliance Against Cancer (MoH-ACC) RCR-2019-23669115Ministry of Health-Alliance Against Cancer (MoH-ACC) WG6-ACC-2020
6 · The paper itself

Abstract

backgroundUveal melanoma (UM) represents the most common primary intra-ocular malignancy in adults. Up to 50% of the patients develop distant metastases within 10 years from diagnosis, with the liver as the most common site. Upon metastatization, life expectancy strongly reduces and immune checkpoint inhibitors that prove effective in cutaneous melanoma do not modify clinical outcome. To date, few studies have focused on deciphering the immunomodulatory features of metastatic UM microenvironment, and there are no prognostic models for clinical use. This highlights the urgent need to understand the delicate interplay between tumor and immune cells acting at the site of metastasis.

methodsWe collected a patient cohort comprising 21 metastatic UM patients. Hepatic and extra-hepatic UM metastasis samples were studied by multiplex immunofluorescence to assess the tumor immune cell composition. Quantitative analyses were performed to correlate immune cell densities with treatment response, metastasis site and patient survival.

resultsCompared to patients with progressive disease, those with controlled disease had a higher intra-tumoral/peritumoral ratio of CD8 + Granzyme B+ cells, higher density of intra-tumoral CD8+ cytotoxic T lymphocytes (CTL) and an increased percentage of UM cells in close proximity to T lymphocytes, reflecting a role of tumor-killing T cells in the disease. In liver metastases (LM), the intra-tumoral densities of CD163+ tumor-associated macrophages (TAM) and of total CD8+ T cells were higher than in extra-hepatic UM metastases, but the percentage of Granzyme B+ CTL was lower. Moreover, LM displayed more UM cells adjacent to both CTL and TAM, and also more T cells in proximity to TAM, all signs of an impaired immune response. The percentage of activated CTL within the tumor represented a prognostic indicator, as patients with a higher intra-tumoral percentage of CD8 + Granzyme B+ cells had the better outcome. A temptative Immunoscore was generated and proved capable to stratify patients with improved survival. Finally, CD4 + FoxP3+ T cells appeared a crucial population for response to immunotherapy.

conclusionThe results of this study underly the clinical relevance and functional importance of composition and localization of antitumor effector cells for the progression of UM metastasis.

Indexed as

AgedFemaleHumansMaleMelanomaMiddle AgedNeoplasm MetastasisSurvival AnalysisTumor MicroenvironmentUveal MelanomaUveal NeoplasmsImmune biomarkersImmune cellImmune contextureMetastatic uveal melanomaTumor microenvironment

Identifiers

PMID33947438
PMCPMC8097926
OpenAlexW3158260811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.